Science
Our approach
TCR-based therapies are an emerging class of drugs leveraging the recognition of tumour-associated antigens to promote targeted cytotoxicity of malignant cells. Soluble TCR approaches provide a unique mechanism of action that addresses many obstacles associated with targeting solid tumours, enabling:
-
Targeting of intracellular antigens
-
High-affinity binding to low-copy number peptide targets
-
Tumour-targeted biodistribution
-
Sustained recruitment of effector immune cells
Targeting solid tumours with soluble TCRs
Soluble TCR therapies, however, pose a development challenge requiring multiparameter protein engineering to identify stable, highly potent TCRs that induce durable antitumour responses with no relevant off-target activity.
Engimmune’s proprietary AI-guided platforms accelerate the development of stable, soluble, multi-specific TCRs with extremely high affinity for their target antigens. We couple protein engineering with functional screening, machine learning and innovative high-throughput solutions to rapidly deliver specificity- and affinity-enhanced soluble TCR (specTR) immune cell engagers. Our specTR molecules are designed using a biology-driven approach and optimized across multiple parameters, including affinity, manufacturability, function and safety, to achieve a more efficient redirection of antitumour immunity.
Safety first
Our unique technologies enable Engimmune to screen for potential off-target effects at the start of the engineering process, resulting in early identification of highly de-risked candidates. We call this approach “specificity-guided affinity maturation,” which greatly increases both the speed and efficiency of clinical candidate selection activities.
Combining protein engineering and AI to rapidly deliver specTR therapeutics
